Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved ...

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

The drug, lenalidomide, has been shown to improve remission time in eligible patients and prolong life. Prof Graham Jackson from Freeman Hospital called it a "massive change". The disease goes ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

Lenalidomide, an analog of thalidomide, was developed because of its more potent anti-MM activity and better toxicity profile than the parent compound. Since its introduction in 2004, lenalidomide ...

Daratumumab therapy resulted in superior progression-free survival in frail patients with previously untreated multiple myeloma.

Opens in a new tab or window SAN DIEGO -- Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and rituximab (Rituxan) resulted in ...

DARZALEX FASPRO ® is a prescription medicine used to treat adult patients with multiple myeloma: · in combination with the medicines bortezomib, lenalidomide, and dexamethasone in newly ...

Tafasitamab increased progression free survival by about 9 months when compared to placebo, according to recent study data.